 |
 |
OncoGEN group is one of the specialized groups in the field of diagnosis, management and selection of treatment approach based on the genetic profile of people. This collection, using the new technologies of next generation sequencing and the use of artificial intelligence, can use the personalized genetic profile in order to target the treatment. OncoGEN has prepared special packages for common diseases in which gene profiling can play a role in managing their treatment, including: cancer, cardiovascular diseases, nervous system abnormalities, eye defects and congenital genetic disorders...
MORE...
|
|
 |
All informations about our health are hidden in our genes. SMARTests is a range of genetic tests that are designed to screen your DNA for known genetic markers. These markers, also known as variants, are associated with risks for diseases, disorders, conditions or traits. The results from the SMARTests can help you manage your health, and the health of your loved ones...
MORE...
|
 |
 |
...
It is a leading specialized group in the field of cancer that by analyzing the DNA of the patient's tumor cell (cancer profile) in addition to the optimal monitoring of cancer, allows the selection of the most appropriate drug for specific treatment. This leading group in the field of modern medical diagnosis and with a team consisting of experienced specialists has taken a new step in the field of cancer diagnosis and treatment...
MORE...
|
 |
 |
BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing essays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well-documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery ...
MORE...
|
 |
 |
PredicineATLAS™ assay is designed to help biopharmaceutical partners identify patients with the right molecular profile for their clinical program, assess response to investigational drugs or combination therapies, and detect presence of residual disease, recurrence, or relapse ...
MORE...
|
|
 |
Signatera is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools ...
MORE...
|
|
 |
Designed to deliver critical information to guide chemotherapy decision-making, Immunoscore® can be used in Stage II localized colon cancer to help physicians identify patients who may be spared adjuvant chemotherapy, and in Stage III localized colon cancer to inform them about the optimal treatment duration for their patients ...
MORE...
|
|
 |
DecisionDx-Melanoma is a validated 31-gene expression profile (GEP) test that was developed to identify the risk of recurrence or metastasis including the likelihood of sentinel lymph node positivity for patients with stage I, II, or III melanoma and inform patient management decisions ...
MORE...
|
|
 |
EndoPredict (EP) is an RNA-based multigene test that predicts the likelihood of distant recurrence in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) who are being treated with adjuvant endocrine therapy ...
MORE...
|
|
 |
Prolaris is a genomic test that analyzes changes in 46 genes in prostate biopsy tissue. It generates a risk score to help predict the likelihood of disease progression in men with localized prostate cancer ...
MORE...
|
|
 |
MyChoice is a test provided by the American Myriad company. This test, using NGS method and genomic analysis of tissue samples of patients with ovarian, prostate, breast and pancreatic cancers, can inform the doctor about the disease and its progress, as well as treatment solutions. Inform ahead. This test has been approved by the American Food and Drug Administration (FDA) ...
MORE...
|